Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

NCT ID: NCT03292484

Last Updated: 2024-12-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

911 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-02

Study Completion Date

2023-04-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is enrolling participants by invitation only. This is an open-label, international, longer-term extension study for eligible subjects who have participated in one of the Aimmune AR101 clinical studies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peanut Allergy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

AR101 Characterized Peanut Allergen OIT (oral immunotherapy) Peanut Allergy Allergy Peanut-Allergic Children Peanut-Allergic Adults Desensitization CPNA (Characterized Peanut Allergen)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AR101

Eligible participants who participated in a prior AR101 study received or continued initial dose escalation, up-dosing, and maintenance of AR101 at 300 milligrams (mg) per day until discontinuation criteria was met (maximum exposure: 4.8 years).

Group Type EXPERIMENTAL

AR101

Intervention Type BIOLOGICAL

AR101

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AR101

AR101

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Prior participation in an Aimmune AR101 clinical study or any future clinical study that identifies ARC008 as a follow-on study option in the protocol
* Written informed consent and/or assent from subjects/guardians as appropriate
* Use of effective birth control by sexually active female subjects of childbearing potential

Exclusion Criteria

* Did not complete a minimum of 3 months of AR101 maintenance therapy if the subject was assigned to AR101 in the parent study
* Currently receiving or received within 5 years prior to Screening any type of peanut or other food allergen immunotherapy, except AR101 or unless allowed in the parent study, and except during the follow-up observation period in this study
* Discontinued early from the parent study
Minimum Eligible Age

1 Year

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aimmune Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jen Garcia

Role: STUDY_CHAIR

Director, Clinical Operations

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alabama Allergy and Asthma Center

Birmingham, Alabama, United States

Site Status

Medical Research of Arizona, Allergy, Asthma & Immunology Associates

Scottsdale, Arizona, United States

Site Status

Banner Univ. of Arizona Medical Center

Tucson, Arizona, United States

Site Status

Arkansas Children's Hospital

Little Rock, Arkansas, United States

Site Status

Jonathan Corren, M.D., Inc.

Los Angeles, California, United States

Site Status

Children's Hospital Los Angeles, Division of Clinical Immunology and Allergy

Los Angeles, California, United States

Site Status

Allergy & Asthma Associates of Southern California

Mission Viejo, California, United States

Site Status

Sean N. Parker Center for Allergy and Asthma Research LPCH El Camino Hospital

Mountain View, California, United States

Site Status

Stanford University

Palo Alto, California, United States

Site Status

Peninsula Research Associates

Rolling Hills Estates, California, United States

Site Status

Allergy & Asthma Medical Group and Research Center

San Diego, California, United States

Site Status

Rady Children's Hospital, Div. of Allergy & Immunology

San Diego, California, United States

Site Status

UCSF, Benioff Children's Hospital - Allergy and Immunology

San Francisco, California, United States

Site Status

Allergy & Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

UCLA Medical Center, Santa Monica

Santa Monica, California, United States

Site Status

Bay Area Allergy

Walnut Creek, California, United States

Site Status

Children's Hospital Colorado

Aurora, Colorado, United States

Site Status

Asthma & Allergy Associates

Colorado Springs, Colorado, United States

Site Status

National Jewish Health

Denver, Colorado, United States

Site Status

Colorado Allergy & Asthma Centers, P.C.

Denver, Colorado, United States

Site Status

Children's National Health System

Washington D.C., District of Columbia, United States

Site Status

Sher Allergy Specialists - Center for Cough

Largo, Florida, United States

Site Status

Allergy Associates of the Palm Beaches

North Palm Beach, Florida, United States

Site Status

Sarasota Clinical Research

Sarasota, Florida, United States

Site Status

University of South Florida, Asthma Allergy & Immunology Clinical Research Unit

Tampa, Florida, United States

Site Status

Children's Healthcare of Atlanta

Atlanta, Georgia, United States

Site Status

Atlanta Allergy & Asthma Clinic

Marietta, Georgia, United States

Site Status

Idaho Allergy and Research

Eagle, Idaho, United States

Site Status

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, Illinois, United States

Site Status

The University of Chicago Medicine, Comer Children's Hospital

Chicago, Illinois, United States

Site Status

Sneeze, Wheeze, & Itch Associates

Normal, Illinois, United States

Site Status

Riley Children's Specialists

Carmel, Indiana, United States

Site Status

Deaconess Clinic, Inc.

Evansville, Indiana, United States

Site Status

Family Allergy & Asthma Research Institute

Louisville, Kentucky, United States

Site Status

Chesapeake Clinical Research, Inc.

Baltimore, Maryland, United States

Site Status

Johns Hopkins Hospital, Pediatric Clinical Research Unit

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Boston Children's Hospital

Boston, Massachusetts, United States

Site Status

Univ. of Michigan Health System, Div. of Allergy and Clinical Immunology

Ann Arbor, Michigan, United States

Site Status

Clinical Research Institute Inc.

Plymouth, Minnesota, United States

Site Status

Children's Mercy on Broadway

Kansas City, Missouri, United States

Site Status

Atlantic Research Center

Ocean City, New Jersey, United States

Site Status

Princeton Center for Clinical Research

Skillman, New Jersey, United States

Site Status

Northwell Health System

Great Neck, New York, United States

Site Status

Jaffe Food Allergy Institute Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Univ. of Rochester Medical Center, Golisano Children's Hosp.

Rochester, New York, United States

Site Status

University of North Carolina at Chapel Hill, Clinical & Translational Research Center

Chapel Hill, North Carolina, United States

Site Status

Clinical Research of Charlotte

Charlotte, North Carolina, United States

Site Status

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States

Site Status

Bernstein Clinical Research Center, LLC

Cincinnati, Ohio, United States

Site Status

Oklahoma Institute of Allergy and Asthma Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Columbia Asthma & Allergy Clinic

Clackamas, Oregon, United States

Site Status

Baker Allergy, Asthma and Dermatology

Portland, Oregon, United States

Site Status

The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, United States

Site Status

Children's Hospital of Pittsburgh of UPMC

Pittsburgh, Pennsylvania, United States

Site Status

National Allergy and Asthma Research, LLC

North Charleston, South Carolina, United States

Site Status

Le Bonheur Children's Hospital, Outpatient Bldg.

Memphis, Tennessee, United States

Site Status

'Specially for Children Allergy, Asthma and Immunology Clinic

Austin, Texas, United States

Site Status

Specially for Children Allergy, Asthma and Immunology Clinic

Austin, Texas, United States

Site Status

Children's Health

Dallas, Texas, United States

Site Status

Western Sky Medical Research

El Paso, Texas, United States

Site Status

Texas Children's Hospital, Baylor College of Medicine

Houston, Texas, United States

Site Status

Central Texas Health Research

New Braunfels, Texas, United States

Site Status

Virginia Mason Medical Center

Seattle, Washington, United States

Site Status

ASTHMA, Inc. Clinical Research Center

Seattle, Washington, United States

Site Status

McMaster University Medical Center

Hamilton, Ontario, Canada

Site Status

Triple A Lab

Hamilton, Ontario, Canada

Site Status

Cheema Research Inc.

Mississauga, Ontario, Canada

Site Status

Ottawa Allergy Research Corp

Ottawa, Ontario, Canada

Site Status

Gordon Sussman Clinical Research

Toronto, Ontario, Canada

Site Status

Unité de dermatologie Pédiatrique, Hôpital Pellegrin-Enfants

Bordeaux, Cedex, France

Site Status

Hopital Saint Vincent de Paul- Service d'Allergologie

Lille, Cedex, France

Site Status

Jeanne de Flandre Hospital -Paediatric Allergy and Pulmonology Center

Lille, Cedex, France

Site Status

Service d'Allergologie Nouvel Hôpital Civil Hôpitaux Univesitaires de Strasbourg

Strasbourg, Cedex, France

Site Status

Charité Universitaetsmedizin Berlin

Berlin, , Germany

Site Status

University of Frankfurt

Frankfurt, , Germany

Site Status

Cork University Hospital, UCC Department of Paediatrics and Child Health

Cork, , Ireland

Site Status

National Children's Research Centre, Our Lady's Children's Hospital Crumlin

Dublin, , Ireland

Site Status

Azienda Ospedaliera di Padova

Padua, Province Of Padua, Italy

Site Status

Beatrix Children's Hospital, University Medical Center Groningen

Groningen, , Netherlands

Site Status

University Medical Center Groningen

Groningen, , Netherlands

Site Status

Hospital General Universitario Gregorio Marañón

Madrid, , Spain

Site Status

H. Infantil Universitario Niño Jesús, Servicio de Alergia

Madrid, , Spain

Site Status

Madrid Hospital Clinico San Carlos, Servicio de Alergia

Madrid, , Spain

Site Status

Sachsska Children and Youth Hospital

Stockholm, , Sweden

Site Status

Leicester Royal infirmary

Leicester, Leicestershire, United Kingdom

Site Status

James Paget University Hospital

Gorleston-on-Sea, Norfolk, United Kingdom

Site Status

Guy & St Thomas' NHS Foundation Trust, Children Allergies Department

London, , United Kingdom

Site Status

St Mary's Hospital - Paediatric Research Unit

London, , United Kingdom

Site Status

Children's Clinical Research Facility, Royal Manchester Children's Hospital

Manchester, , United Kingdom

Site Status

Sheffield Children's Hospital

Sheffield, , United Kingdom

Site Status

University Hospitals Southampton Foundation NHS Trust

Southampton, , United Kingdom

Site Status

Central Manchester University Hospitals

Wythenshawe, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Germany Ireland Italy Netherlands Spain Sweden United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Nilsson C, Scurlock AM, Dellon ES, Brostoff JM, Pham T, Ryan R, Brown KR, Adelman DC, Aceves SS. Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy. J Allergy Clin Immunol Pract. 2021 Dec;9(12):4496-4501. doi: 10.1016/j.jaip.2021.07.048. Epub 2021 Aug 11. No abstract available.

Reference Type DERIVED
PMID: 34389504 (View on PubMed)

Fernandez-Rivas M, Vereda A, Vickery BP, Sharma V, Nilsson C, Muraro A, Hourihane JO, DunnGalvin A, du Toit G, Blumchen K, Beyer K, Smith A, Ryan R, Adelman DC, Jones SM. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2022 Mar;77(3):991-1003. doi: 10.1111/all.15027. Epub 2021 Sep 24.

Reference Type DERIVED
PMID: 34320250 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ARC008

Identifier Type: -

Identifier Source: org_study_id